Clinical Trials

Classical hematologyGastrointestinal

220 enrolled

Pathologic Complete Response, Digestive System Neoplasms, Gastrointestinal Neoplasms, Pancreatic Neoplasms, Thrombocytopenia, Colorectal Neoplasms

NCT07586826 2026-05-14

N01-A-PICIT-GT

BreastClassical hematologyGynecologicThoracic

220 enrolled

Pathologic Complete Response, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Thrombocytopenia, Endometrial Neoplasms

NCT01042379 2026-05-06

I-SPY

Phase 1 Not yet recruiting

5,000 enrolled

BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT06743555 2026-04-28

SAVED LUNG

14 enrolled

Thoracic

Pathologic Complete Response, Carcinoma, Non-Small-Cell Lung

NCT07538206 2026-04-20

Vebectotamab Vedotin Combined With Pucotelimab in the Treatment of Locally Advanced Laryngeal Carcinoma

Phase 1/2 Not yet recruiting

10 enrolled

Phase 3 Not yet recruiting

Pathologic Complete Response, Head and Neck Neoplasms

NCT07472868 2026-03-16

MEND-IT II

394 enrolled

Pathologic Complete Response

NCT05926024 2026-03-11

Long-Term Follow-Up in Women With Early Breast Cancer Three Years of More Post Primary Treatment

Active not recruiting

253 enrolled

Pathologic Complete Response, Breast Neoplasms

NCT06647680 2026-03-06

Neoadjuvant Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer（CONTROL-01）

35 enrolled

Phase EARLY_PHASE1 Active not recruiting

Pathologic Complete Response, Rectal Neoplasms

NCT03832569 2026-03-05

Study of Pembrolizumab Following Surgery in Patients With Microsatellite Instability High (MSI-H) Solid Tumors

17 enrolled

Pathologic Complete Response

NCT06130995 2026-03-05

Relugolix + Enzalutamide Study in High-Risk Prostate Cancer

Phase 1 Recruiting

46 enrolled

Pathologic Complete Response, Neoplasm, Residual

NCT04055220 2026-02-17

REGOSTA

Phase 2 Not yet recruiting

168 enrolled

Sarcoma

Pathologic Complete Response, Bone Neoplasms, Chondrosarcoma, Hemangiosarcoma, Leiomyosarcoma, Patient Compliance, Sarcoma, Ewing, Osteosarcoma, Histiocytoma, Malignant Fibrous

NCT07397442 2026-02-11

Short-Course Radiotherapy Combined With Chemotherapy and Immunotherapy in Mid-Low Locally Advanced Rectal Cancer

19 enrolled

Pathologic Complete Response, Rectal Neoplasms

NCT07353723 2026-01-20

Nimotuzumab Combined With Toripalimab and Chemotherapy for Locally Advanced Tonsillar Cancer

10 enrolled

Pathologic Complete Response, Head and Neck Neoplasms

NCT07353840 2026-01-20

T-START-CR

160 enrolled

Lymphoid

Pathologic Complete Response, Lymphoma, T-Cell, Peripheral

NCT07328841 2026-01-09

Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and Immunotherapy

Phase 3 Recruiting

456 enrolled

Nasopharyngeal Carcinoma, Pathologic Complete Response

NCT07328854 2026-01-09

40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma

Phase 3 Recruiting

346 enrolled

Nasopharyngeal Carcinoma, Pathologic Complete Response

NCT06364371 2025-12-18

Dynamic Multi-omics Integration Model to Predict Neoadjuvant Therapy Response in Locally Advanced Rectal Cancer

106 enrolled

Pathologic Complete Response

NCT01794572 2025-12-12

TOMMY

Phase NA Terminated

13 enrolled 10 charts

Plasma cell

Pathologic Complete Response, Multiple Myeloma, Recurrence

NCT01844986 2025-12-10

SOLO-1

450 enrolled 18 charts 1 FDA

Gynecologic

Pathologic Complete Response, Ovarian Neoplasms

NCT07007052 2025-11-26

TAGVEN

Phase 2 Not yet recruiting

33 enrolled

Myeloid

Pathologic Complete Response, Blastic Plasmacytoid Dendritic Cell Neoplasm

NCT07066189 2025-10-29

Lifestyle, Exercise, And Nutrition (LEAN) Trial on Pathologic Complete Response in TNBC

160 enrolled

Pathologic Complete Response, Motor Activity, Triple Negative Breast Neoplasms

NCT04229979 2025-10-01

REGAL

Other hematologic neoplasm

127 enrolled

Pathologic Complete Response, Leukemia, Myeloid, Acute

NCT04335669 2025-09-12

NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC

325 enrolled

Phase NA Not yet recruiting

Pathologic Complete Response, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07164872 2025-09-10

Neoadjuvant Chemotherapy Combined With Preoperative Radiotherapy for Locally Advanced Breast Cancer

50 enrolled

Pathologic Complete Response, Breast Neoplasms

NCT07166185 2025-09-10

NEOTRAPSCAL

70 enrolled

Phase NA Active not recruiting

Pathologic Complete Response, Breast Neoplasms

NCT06087718 2025-08-14

Feasibility of the Maastro Applicator in Rectal Cancer

10 enrolled

472 enrolled 24 charts 1 FDA

Pathologic Complete Response, Radiation Injuries, Rectal Neoplasms

NCT06728982 2025-08-01

Impact Of Metformin In Rectal Cancer Patients

Phase 2/3 Completed

85 enrolled

Pathologic Complete Response

NCT01757535 2025-07-08

QUAZAR AML-001

Phase 3 Completed

Other hematologic neoplasm

Pathologic Complete Response, Leukemia, Myeloid, Acute

NCT06811844 2025-07-01

Two-cycle and Three-cycle Induction Therapy With Modified TPF Regimen Combined and Camrelizumab for LANPC

208 enrolled

Pathologic Complete Response, Nasopharyngeal Neoplasms

NCT03522246 2025-06-24

ATHENA

1,097 enrolled 26 charts

Gynecologic

Carcinoma, Ovarian Epithelial, Pathologic Complete Response, Fallopian Tube Neoplasms, Neoplasms

NCT06927180 2025-06-23

SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC

180 enrolled

Pathologic Complete Response, Breast Neoplasms

NCT06111807 2025-03-30

MRD-LUNG

248 enrolled

Thoracic

Pathologic Complete Response, Hypersensitivity, Lung Neoplasms, Neoplasm, Residual

NCT05416164 2025-03-26

DESCARTES: De-ESCAlation of RadioTherapy in Patients With Pathologic Complete rESponse to Neoadjuvant Systemic Therapy

595 enrolled

Pathologic Complete Response, Breast Neoplasms

NCT05976815 2025-03-26

KEYMOVE

86 enrolled

Pathologic Complete Response, Breast Neoplasms, Motor Activity

NCT06889402 2025-03-21

Prognostic Analysis of Esophageal Cancer with Complete Pathological Response After Neoadjuvant Therapy

Not yet recruiting

600 enrolled

LymphoidOther hematologic neoplasm

Esophageal Squamous Cell Carcinoma, Pathologic Complete Response, Esophageal Neoplasms, Recurrence

NCT04314219 2025-03-13

PTCy-PMAT

Phase 3 Recruiting

264 enrolled

Pathologic Complete Response, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05918328 2025-03-07

Comparing the Efficacy of Nab-PH+Pyrrolitinib and TCbHP in the Neoadjuvant Treatment of HER2 Positive BC

610 enrolled

Pathologic Complete Response, Breast Neoplasms

NCT06854107 2025-03-06

Intratumoral and Peritumoral Habitat Radiomics of MRI Predict Pathologic Complete Response to Neoadjuvant Chemoimmunotherapy in Oral Squamous Cell Carcinoma

Completed

225 enrolled

Squamous Cell Carcinoma of Head and Neck, Pathologic Complete Response

NCT06794099 2025-01-27

Study on the Applicability of CCR Criteria in Rectal Cancer

Completed

177 enrolled

Pathologic Complete Response

NCT06755567 2025-01-01

Application of MRI Radiomics Features in Neoadjuvant Therapy of Head and Neck Squamous Cell Carcinoma

Not yet recruiting

750 enrolled

Pathologic Complete Response, Head and Neck Neoplasms

NCT05350722 2024-12-30

ABLATIVE-2

100 enrolled

Pathologic Complete Response, Breast Neoplasms

NCT06276868 2024-12-17

Darsilide Combined With AI, Trastuzumab and Patuzumab in the Neoadjuvant Treatment of HR+/HER2+ Breast Cancer

71 enrolled

Pathologic Complete Response, Breast Neoplasms

NCT05000697 2024-11-27

CCHOWW

216 enrolled

LymphoidOther hematologic neoplasm

Pathologic Complete Response, Rectal Neoplasms

NCT01266083 2024-11-19

WT1 Vaccine Treatment of Patients in Remission From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL)

Phase 2 Completed

22 enrolled 8 charts

Pathologic Complete Response, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04934670 2024-08-27

2002

Phase 3 Terminated

12 enrolled 12 charts

Lymphoid

Pathologic Complete Response, Lymphoma, Follicular

NCT04435197 2024-07-03

PALACE-2

Phase 2 Completed

143 enrolled

Esophageal Squamous Cell Carcinoma, Pathologic Complete Response

NCT01340430 2024-05-09

Neoadjuvant 5-fluorouracil, Epirubicin and Cyclophosphamide (FEC) Followed by Weekly Paclitaxel and Trastuzumab in Her2 Positive Breast Cancer

Phase 2 Completed

43 enrolled

Pathologic Complete Response

NCT05659056 2024-04-16

Neoadjuvant Study With Pyrotinib and Trastuzumab and Abraxane in Patients With HER2-enriched Breast Cancer

Phase 2 Unknown

65 enrolled